Category Ranking
98%
Total Visits
921
Avg Visit Duration
2 minutes
Citations
20
Article Abstract
A novel indirect immuno-polymerase chain reaction (I-PCR) assay was developed for the detection of circulating anti-Ag85B (antigen 85B, Rv1886c), anti-ESAT-6 (early secretory antigenic target-6, Rv3875) and anti-cord factor (trehalose 6,6'-dimycolate) antibodies from the sera samples of pulmonary tuberculosis (PTB) and extrapulmonary tuberculosis (EPTB) patients and the results were compared with an analogous enzyme-linked immunosorbent assay (ELISA). We covalently attached the amino-modified reporter DNA to the dithiothreitol (DTT)-reduced anti-human IgG antibody through a chemical linker succinimidyl 4-[N-maleimidomethyl]-cyclohexane-1-carboxylate (SMCC). The detection of cocktail of anti-Ag85B, anti-ESAT-6 and anti-cord factor antibodies was found to be superior to the detection of individual antibodies. The sensitivities of 89.5% and 77.5% with I-PCR and 70.8% and 65% with ELISA were observed in smear-positive and smear-negative PTB cases, respectively with high specificity (90.9%). On the other hand, a sensitivity of 77.5% with I-PCR and 65% with ELISA was observed in EBTB cases. The detection of cocktail of antibodies by I-PCR is likely to improve the utility of existing algorithms for TB diagnosis.
Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1016/j.mimet.2015.11.016 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Therapeutic vaccination with the Ag85B-Rv2660c-MPT70 fusion protein enhances H37Ra clearance in post-exposure mice.
Front Immunol
September 2025
Center for Infectious Diseases and Vaccine Research, West China Hospital, West China School of Medicine, Sichuan University, Chengdu, China.
Latent tuberculosis infection (LTBI), affecting nearly one-quarter of the global population, represents a major barrier to Tuberculosis (TB) eradication and a paradigm of chronic infectious disease. Current chemotherapeutic regimens for TB, although effective, are limited by drug resistance, toxicity, and poor adherence, underscoring the urgent need for alternative strategies. In this study, we investigated ARM-a recombinant fusion protein comprising Ag85B, Rv2660c, and MPT70-as a therapeutic vaccine in a murine model of post-exposure () infection.
View Article and Find Full Text PDFA heterologous prime-boost regimen using BCG and an mRNA encoding Ag85B heightens immune response in mice.
Biochem Biophys Res Commun
September 2025
Center of Excellence in Vaccine Research and Development (Chula Vaccine Research, Center-Chula VRC), Faculty of Medicine, Chulalongkorn University, Bangkok, 10330, Thailand; Department of Microbiology, Faculty of Science, Chulalongkorn University, Bangkok, 10330, Thailand. Electronic address: tanapa
The mRNA vaccine platform holds a great promise as novel tuberculosis vaccine. In this study, the use of mRNA encoding Ag85B from M. tuberculosis (M.
View Article and Find Full Text PDFEnhancing Mycobacterium tuberculosis-Ag85B immunogenicity by fusing with human Fcγ1 (Ag85B:hFcγ1).
Microb Pathog
October 2025
Cancer and Immunology Research Center, Research Institute for Health Development, Kurdistan University of Medical Sciences, Sanandaj, Iran. Electronic address:
Tuberculosis (TB) is still a life-threatening infection. Mycobacterium tuberculosis (Mtb) Ag85 is the most potent immunogenic factor for introducing protective vaccines against TB. To enhance its immunogenicity, Mtb Ag85B was fused to the Fc fragment of human IgG1 to produce Ag85B:hFcγ1 and its immunogenicity was assessed in a mouse model.
View Article and Find Full Text PDFDevelopment of a Femtosensitive Electrochemical Aptasensor for Tuberculosis Ag85B Detection.
Anal Chem
July 2025
Department of Chemical Engineering, Pohang University of Science and Technology (POSTECH), Pohang 37673, Republic of Korea.
Tuberculosis (TB) disease continues to pose a major global health challenge, particularly in resource-limited settings where access to rapid, sensitive, and affordable diagnostic tools remains limited. Traditional methods, such as sputum smear microscopy and culture techniques, are time-consuming, lack sensitivity, and often require well-equipped laboratories, making them unsuitable for rapid, point-of-care diagnostics. To address these challenges, developing a rapid, sensitive, and selective biosensor is essential for the early detection of TB.
View Article and Find Full Text PDFmulti-epitope-based vaccine design for complex species.
Front Immunol
June 2025
Medical Microbiology Unit, Department of Laboratory Diagnostic and Investigative Sciences, Faculty of Medicine and Health Sciences, University of Zimbabwe, Harare, Zimbabwe.
Introduction: The complex (MAC)-comprising , , and-is an emerging group of opportunistic pathogens responsible for significant morbidity and mortality, particularly in immunocompromised individuals. Despite this growing burden, no vaccines currently provide cross-species protection. In silico vaccine design offers a rapid, cost-effective strategy to identify immunogenic epitopes and assemble multi-epitope constructs with optimized safety and efficacy.
View Article and Find Full Text PDF